Tadalafil
Deep-Dive: ETLAS-2 — Tadalafil for CSVD Fails Feasibility, but the Imaging Signal Hints at a Better Trial
ETLAS-2 phase II: tadalafil 20 mg daily for 3 months in CSVD fails feasibility (compliance 68% vs 94% placebo) with 2-fold more AEs; per-protocol WMH volume trend suggests mechanistic signal at lower doses.